DK2361928T3 - Trunkerede fragmenter af alpha-synuklein i Lewy body-sygdom - Google Patents

Trunkerede fragmenter af alpha-synuklein i Lewy body-sygdom Download PDF

Info

Publication number
DK2361928T3
DK2361928T3 DK10189868.2T DK10189868T DK2361928T3 DK 2361928 T3 DK2361928 T3 DK 2361928T3 DK 10189868 T DK10189868 T DK 10189868T DK 2361928 T3 DK2361928 T3 DK 2361928T3
Authority
DK
Denmark
Prior art keywords
synuclein
alpha
fragment
agent
antibody
Prior art date
Application number
DK10189868.2T
Other languages
English (en)
Inventor
Tamie J Chilcote
Jason Goldstein
Wei Ping Gai
John P Anderson
Original Assignee
Prothena Biosciences Ltd
The Flinders Univ Of South Australia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd, The Flinders Univ Of South Australia filed Critical Prothena Biosciences Ltd
Application granted granted Critical
Publication of DK2361928T3 publication Critical patent/DK2361928T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Environmental Sciences (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Toxicology (AREA)
  • Animal Husbandry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Analytical Chemistry (AREA)
  • Psychology (AREA)

Claims (14)

1. Antistof der specifikt binder til et 1-122 eller 1-119 fragment af alpha-synuklein, uden specifikt at binde til alpha-synuklein i hele dens længde som defineret i SEQ ID No.l, eller et fragment der inducerer dette antistof hvor fragmentet der inducerer antistoffet har færre end 20 aminosyrer af alpha-synuklein og omfatter C-terminus af 1-122 eller 1-119 fragmentet af alpha-synuklein.
2. Antistof ifølge krav 1 der er et humant eller humaniseret antistof, fortrinsvis af human isotype-IgGl.
3. Antistof ifølge krav 1 eller krav 2, eller fragmentet der inducerer antistoffet ifølge krav 1, til anvendelse til behandling eller profylakse af Lewy body-sygdom.
4. Antistof ifølge krav 1 eller krav 2 til anvendelse til at diagnosticere tilstedeværelsen eller modtageligheden over for en LBD hvor antistoffet bliver indgivet til en patient og antistoffets bindingsniveau hos patienten bliver bestemt, hvor et højere niveau af binding i forhold til et basislinjeniveau hos personer der ikke er syge indikerer tilstedeværelse af eller modtagelighed over for LBD.
5. Fragment af alpha-synuklein med fuld længde som defineret i SEQ ID No.l, der er alpha-synuklein 1-122 eller 1-119.
6. Fragment ifølge krav 5, hvor fragmentet af alpha-synuklein bæreren mutation forbundet med arvelig Lewy Body-sygdom (LBD), eventuelt en A53T-mutation.
7. Fragment af alpha-synuklein som defineret i krav 5 eller krav 6 enten i kombination med en adjuvans der øger et immunrespons omfattende antistoffer til fragmentet, eller forbundet med en bærer der danner et fusionsprotein, hvor bæreren øger et immunrespons omfattende antistoffer til fragmentet.
8. In vitro fremgangsmåde til at screene for et middel med en farmakologisk aktivitet der er egnet til at behandle en LBD omfattende: at bringe midlet i kontakt med et fragment af alpha-synuklein som defineret i krav 5 eller krav 6; og at bestemme aggregationshastigheden eller -omfanget af fragmentet af alpha-synuklein, hvor en reduktion af aggregationshastigheden eller -omfanget i forhold til en kontrol uden midlet indikerer at midlet har den farmakologiske aktivitet.
9. In vitro fremgangsmåde til at screene et middel for en farmakologisk aktivitet der er egnet til at behandle en LBD, omfattende: at bringe en celle der udtrykker alpha-synuklein og bearbejder alpha-synuklein til et fragment som defineret i krav 5 eller krav 6 i kontakt med midlet; og at bestemme et niveau af fragmentet i cellen i forhold til et basislinjeniveau i den samme celletype i fravær af midlet, en reduktion af niveauet af fragmentet i forhold til basislinjen der indikerer at midlet har den farmakologiske aktivitet der er egnet til at behandle en LBD; hvor cellen fortrinsvis er en menneskecelle, mere fortrinsvis en neuronal celle eller en dopaminerg celle.
10. Fremgangsmåde til at screene for et middel med en farmakologisk aktivitet der er egnet til at behandle en LBD, omfattende at bringe et ikke-humant transgent dyr der udtrykker et fragment af alpha-synuklein som defineret i krav 5 eller krav 6 i kontakt med midlet; og at bestemme et niveau af aggregerede former af fragmentet i hjernen på det transgene dyr i forhold til et basislinjeniveau af aggregerede former af fragmentet hos et sammenligneligt transgent dyr ved fraværet af midlet, en reduktion af niveauet af de aggregerede former fragment i forhold til basislinjen der indikerer at midlet har en farmakologisk aktivitet der er egnet til at behandle en LBD, hvor det transgene dyr fortrinsvis er en mus eller en Drosophila.
11. Fremgangsmåde til at screene et middel for en farmakologisk aktivitet der er egnet til at behandle en LBD, omfattende at bringe et ikke-humant transgent dyr med et transgen der udtrykker alpha-synuklein og bearbejder alpha-synuklein til et fragment som defineret in krav 5 eller krav 6 i kontakt med midlet; og at bestemme et niveau af fragmentet i en neuronal celle i forhold til et basislinjeniveau i fraværet af midlet, en reduktion af niveauet af fragmenterne i forhold til basislinjen der indikerer at midlet har den farmakologiske aktivitet der er egnet til at behandle LBD.
12. Transgent ikke-humant dyr, fortrinsvis en mus eller Drosophila, med et genom omfattende et transgen omfattende: en promotor virksomt forbundet med et nukleinsyresegment der koder for et fragment af alpha-synuklein som defineret i et hvilket som helst af krav 5 eller krav 6, hvor ekspression af fragmentet hos det transgene dyr disponerer dyret til at udvikle mindst et kendetegn ved en LBD, hvor promotoren fortrinsvis er en PDGF-promotor, eller hvor det mindst ene kendetegn fortrinsvis er en svækkelse af bevægefunktion eller en svækkelse af kognitiv funktion.
13. In vitro fremgangsmåde til at detektere tilstedeværelse eller modtagelighed over for en LBD hos en patient, omfattende: at detektere et niveau af et fragment af alpha-synuklein som defineret i krav 5 eller krav 6 i en prøve af rygmarvsvæske, et niveau der er højere end et basislinjeniveau hos personer der ikke er syge indikerer tilstedeværelse af eller modtagelighed over for LBD.
14. Fremgangsmåde til at screene for en protease der spalter intakt alpha-synuklein for at danne et fragment som defineret i krav 5 eller krav 6 omfattende: at identificere en inhibitor af proteasen; at bringe inhibitoren i kontakt med et celle- eller vævsekstrakt indeholdende proteasen, hvorved proteasen binder til inhibitoren; og at frigøre proteasen fra inhibitoren, eventuelt hvor inhibitoren er et peptid af alpha-synuklein omfattende et tilstødende segment af mindst 5 rester af intakt alpha-synuklein mellem positioner 115 og 130, fortrinsvis hvor peptidet omfatter et tilstødende segment af mindst 5 rester mellem positioner 118 og 122, mere fortrinsvis hvor mindst en af resterne er en overgangstilstandsanalog.
DK10189868.2T 2003-05-19 2004-05-19 Trunkerede fragmenter af alpha-synuklein i Lewy body-sygdom DK2361928T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47192903P 2003-05-19 2003-05-19
EP04776059.0A EP1633189B1 (en) 2003-05-19 2004-05-19 Truncated fragments of alpha-synuclein in lewy body disease

Publications (1)

Publication Number Publication Date
DK2361928T3 true DK2361928T3 (da) 2017-07-03

Family

ID=34135040

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10189868.2T DK2361928T3 (da) 2003-05-19 2004-05-19 Trunkerede fragmenter af alpha-synuklein i Lewy body-sygdom
DK04776059.0T DK1633189T3 (da) 2003-05-19 2004-05-19 Trunkerede fragmenter af alfa-synuklein i lewy body-sygdom

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK04776059.0T DK1633189T3 (da) 2003-05-19 2004-05-19 Trunkerede fragmenter af alfa-synuklein i lewy body-sygdom

Country Status (12)

Country Link
US (1) US7306945B2 (da)
EP (2) EP1633189B1 (da)
JP (2) JP4820291B2 (da)
CA (1) CA2526900C (da)
CY (2) CY1119133T1 (da)
DK (2) DK2361928T3 (da)
ES (2) ES2632216T3 (da)
HU (2) HUE035044T2 (da)
PL (2) PL1633189T3 (da)
PT (2) PT2361928T (da)
SI (2) SI1633189T1 (da)
WO (1) WO2005013889A2 (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040146521A1 (en) * 1999-06-01 2004-07-29 Schenk Dale B. Prevention and treatment of synucleinopathic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8697082B2 (en) 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US8506959B2 (en) * 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
TW200509968A (en) * 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US7358331B2 (en) * 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
US7550649B2 (en) 2003-10-30 2009-06-23 Taisho Pharmaceutical Co., Ltd. Transgenic non-human mammal
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
MX2007001679A (es) 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
US20070214509A1 (en) * 2005-12-23 2007-09-13 The Parkinson's Institute Methods and systems for identifying compounds that modulate alpha-synuclein aggregation
US20090010894A1 (en) * 2005-12-23 2009-01-08 The Parkinson's Institute Methods and systems for identifying compounds that modulate alpha-synuclein aggregation
PL2583978T3 (pl) 2007-02-23 2016-07-29 Prothena Biosciences Ltd Co Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych
LT3067066T (lt) 2007-02-23 2019-06-25 Prothena Biosciences Limited Sinukleopatinių ir amiloidogeninių ligų prevencija ir gydymas
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
AT506535B1 (de) * 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
WO2009128948A1 (en) * 2008-04-17 2009-10-22 Peptimmune, Inc. Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
ES2709048T3 (es) 2008-04-29 2019-04-15 Bioarctic Ab Anticuerpos y vacunas para su uso en métodos terapéuticos y diagnósticos para trastornos relacionados con alfasinucleína
AT508638B1 (de) 2009-08-21 2011-08-15 Affiris Ag Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
JP6006908B2 (ja) * 2010-11-05 2016-10-12 ブランダイス ユニバーシティBrandeis University Ice阻害化合物およびその使用
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
WO2013173827A2 (en) * 2012-05-18 2013-11-21 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting diseases of the central nervous system
US11191832B2 (en) 2013-11-19 2021-12-07 Prothena Biosciences Limited Monitoring immunotherapy of Lewy body disease from constipation symptoms
JP2017536102A (ja) 2014-10-16 2017-12-07 ジェネンテック, インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
TW202309093A (zh) 2016-06-02 2023-03-01 英商梅迪繆思有限公司 針對α-突觸核蛋白之抗體及其用途
US20190227082A1 (en) * 2016-07-06 2019-07-25 Prothena Biosciences Limited Assay for detecting total and s129 phosphorylated alpha-synuclein
RU2019114679A (ru) 2016-11-15 2020-12-17 Х. Лундбекк А/С Средства, пути применения и способы лечения синуклеопатии
EP3555127B1 (en) 2016-12-16 2024-12-18 H. Lundbeck A/S Agents, uses and methods
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル-マイヤーズ スクイブ カンパニー アルファ-シヌクレインに対する抗体およびその使用
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
EP3752840A4 (en) * 2018-02-12 2022-08-10 The Scripps Research Institute PROCEDURES RELATED TO PARKINSON'S DISEASE AND SYNUCLEINOPATHIES
CN112105393A (zh) 2018-05-16 2020-12-18 爱默蕾大学 苯乙烯基苯并噻唑衍生物及在成像中的用途
MX2021007446A (es) * 2018-12-19 2021-09-08 United Biomedical Inc Epítopos artificiales promiscuos de linfocitos t colaboradores como estimuladores inmunes para inmunógenos peptídicos sintéticos.
JP7898188B2 (ja) 2020-08-04 2026-07-31 エイシー イミューン ソシエテ アノニム 免疫原性化合物
KR102505164B1 (ko) * 2020-09-29 2023-02-28 서울대학교산학협력단 신경퇴행성 질환의 예방 또는 치료용 펩타이드 및 이를 포함하는 약학 조성물
IL311344A (en) * 2021-09-16 2024-05-01 H Lundbeck As Preparations and methods for the treatment of synoclinopathies
CN118475836A (zh) 2021-11-01 2024-08-09 硝酸酶治疗公司 诊断突触核蛋白病的方法
WO2024240186A1 (zh) 2023-05-22 2024-11-28 深圳博芮健制药有限公司 含硫稠环化合物、含其的药物组合物、其制备方法及其应用
WO2025172592A1 (en) 2024-02-15 2025-08-21 Ac Immune Sa Alpha synuclein therapeutic vaccine

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2109945T3 (es) 1990-06-01 1998-02-01 Chiron Corp Composiciones y procedimientos para identificar moleculas biologicamente activas.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1993001222A1 (fr) 1991-07-03 1993-01-21 Kanebo, Ltd. Elastomere de polyurethane thermoplastique, procede et dispositif de production, et fibre elastique realisee a partir de cet elastomere
EP0604552B1 (en) 1991-09-18 1997-02-12 Affymax Technologies N.V. Method of synthesizing diverse collections of oligomers
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
DE69233109T2 (de) 1992-01-07 2004-05-19 Elan Pharmaceuticals, Inc., San Francisco Transgene tiermodelle fur alzheimer-krankheit
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
HUT72495A (en) 1992-10-01 1996-05-28 Cold Spring Harbor Lab Complex combinatorial chemical libraries encoded with tags
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
JPH09508353A (ja) 1993-11-02 1997-08-26 アフィマックス テクノロジーズ ナムローゼ フェンノートシャップ 分子多様性の合成及びスクリーニング
US5914349A (en) 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
JPH10500112A (ja) 1994-05-06 1998-01-06 ファーマコピーア,インコーポレイテッド 組合せ ジヒドロベンゾピラン ライブラリー
US5663046A (en) 1994-06-22 1997-09-02 Pharmacopeia, Inc. Synthesis of combinatorial libraries
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU3117799A (en) * 1998-03-30 1999-10-18 Trustees Of The University Of Pennsylvania, The Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders
US6184351B1 (en) * 1998-09-25 2001-02-06 Amgen Inc. α-synuclein super-mutants accelerate α-synuclein aggregation
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
CN1440420A (zh) * 2000-07-07 2003-09-03 万能药制药公司 预防神经组织损伤和治疗α-共核蛋白疾病的方法
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease

Also Published As

Publication number Publication date
EP2361928B1 (en) 2017-04-26
WO2005013889A3 (en) 2005-04-28
WO2005013889A2 (en) 2005-02-17
EP1633189B1 (en) 2017-07-05
US7306945B2 (en) 2007-12-11
CA2526900A1 (en) 2005-02-17
PL1633189T3 (pl) 2017-12-29
PT2361928T (pt) 2017-07-21
HUE035044T2 (en) 2018-05-02
SI1633189T1 (sl) 2017-12-29
HUE034320T2 (en) 2018-02-28
ES2640669T3 (es) 2017-11-03
JP4820291B2 (ja) 2011-11-24
CY1119133T1 (el) 2018-02-14
EP1633189A2 (en) 2006-03-15
JP2011033633A (ja) 2011-02-17
CY1119556T1 (el) 2018-03-07
PL2361928T3 (pl) 2017-09-29
JP5766923B2 (ja) 2015-08-19
JP2007525464A (ja) 2007-09-06
US20050198694A1 (en) 2005-09-08
CA2526900C (en) 2015-11-24
ES2632216T3 (es) 2017-09-11
EP1633189A4 (en) 2006-07-19
SI2361928T1 (sl) 2017-07-31
EP2361928A1 (en) 2011-08-31
DK1633189T3 (da) 2017-08-21
WO2005013889A9 (en) 2005-06-02
PT1633189T (pt) 2017-10-04

Similar Documents

Publication Publication Date Title
DK1633189T3 (da) Trunkerede fragmenter af alfa-synuklein i lewy body-sygdom
EP2371396B1 (en) Truncated fragments of alpha synuclein in lewy body disease
JP2012041338A (ja) Synuclein病の予防および治療
CA2912912C (en) Truncated fragments of alpha-synuclein in lewy body disease
HK1161605B (en) Truncated fragments of alpha-synuclein in lewy body disease
HK1161605A (en) Truncated fragments of alpha-synuclein in lewy body disease
HK1162355B (en) Truncated fragments of alpha synuclein in lewy body disease
HK1153126B (en) Truncated fragments of alpha-synuclein in lewy body disease